Zealand Pharma upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst Laura Hindley upgraded Zealand Pharma (ZLDPF) to Overweight from Equal Weight with a DKK 750 price target The ...
Zealand Pharma completes enrollment in ZUPREME-1 trial
Zealand Pharma (ZLDPF) announced that the last participant has been enrolled and randomized to active treatment or placebo in ZUPREME-1, a ...
William Blair Forecasts OTCMKTS:ZLDPF FY2025 Earnings
Equities research analysts at William Blair lowered their FY2025 earnings per share estimates for shares of Zealand Pharma A/S in a research note issued to investors on Wednesday, March 12th. William ...
Roche signs $5.3 billion deal with Danish obesity drugmaker, Novo stock slides 4%
Roche (RHHBY) is increasing its investment into the obesity space with an up to $5.3 billion deal with Danish drugmaker Zealand Pharma (ZLDPF), the companies announced Wednesday. The deal would give ...
Roche-Zealand deal is the latest to boost obesity space
Shares of weight loss drug developers gained on Wednesday after Roche (OTCQX:RHHBF) announced a multi-billion-dollar deal with Danish biotech Zealand Pharma (OTCPK:ZLDPF) to jointly develop an obesity ...
Roche And Zealand Team Up To Develop Petrelintide
Roche & Zealand join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. Find out why this deal is a win-win for RHHBY & ZLDPF.
Yahoo Finance14d
Roche signs $5.3 billion deal with Danish obesity drugmaker, Novo Nordisk stock slides 4%
Roche (RHHBY) is increasing its investment into the obesity space with an up to $5.3 billion deal with Danish drugmaker Zealand Pharma (ZLDPF), the companies announced Wednesday. The deal would ...
Roche, Zealand Pharma enter $5.3B license deal for obesity treatment
Roche (OTCQX:RHHBY) is looking to boost its presence in the booming weight-loss market through an exclusive collaboration and licensing deal with Danish biotech Zealand Pharma (OTCPK:ZLDPF). Under the ...